Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept

NCT04287348 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped due to safety letter beovu from Novartis

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Brolucizumab 6 mg solution for intravitreal injection

Sponsor

Vista Klinik

Collaborators

[object Object]